PTC Therapeutics, Inc. (PTCT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Warren, NJ, United States. Der aktuelle CEO ist Matthew Klein.
PTCT hat IPO-Datum 2013-06-20, 939 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $6.04B.
PTC Therapeutics, Inc. is a biopharmaceutical company headquartered in South Plainfield, New Jersey, dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company's commercial portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy treatment across the United States, European Economic Area, Brazil, and Russia; Tegsedi and Waylivra for rare disease treatment in Latin America and the Caribbean; and Evrysdi for spinal muscular atrophy in Brazil. PTC Therapeutics maintains a robust pipeline of candidates in clinical, pre-clinical, and research stages, including PTC518 for Huntington's disease, supported by its proprietary splicing platform technology. The company collaborates with leading partners including Roche and the Spinal Muscular Atrophy Foundation to advance drug discovery and commercialization efforts in regenerative medicine and rare disease treatment globally.
